dehydroepiandrosterone has been researched along with Androgen Insensitivity Syndrome in 27 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pregnenolone was converted to testosterone in the right testis at a rate of 6,61% and in the left testis at a rate of 3,23%." | 1.25 | Steroid metabolism in the gonads of a patient with testicular feminization. I. Metabolism of cholesterol, pregnenolone, progesterone and dehydroepiandrosterone in vitro. ( Schindler, AE, 1975) |
| "The seven cases of testicular feminization were classified as 'complete' or 'incomplete' forms of the syndrome by reference to clinical data and the histology of the testicular tissue." | 1.25 | Studies of in vitro steroid metabolism by testis tissue from 'complete' and 'incomplete' forms of testicular feminization. ( Bell, JB, 1975) |
| "In 22 children with male pseudohermaphroditism, plasma concentrations of testosterone and dehydroandrosterone sulfate were measured before and after HCG stimulation." | 1.25 | Children with male pseudohermaphroditism: endocrine and metabolic studies. ( Bertrand, J; De Peretti, E; Frederich, A; Saez, JM, 1971) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 27 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| KASE, N | 1 |
| MORRIS, JM | 1 |
| NEHER, R | 1 |
| KAHNT, FW | 1 |
| ROVERSI, GD | 1 |
| BOMPIANI, A | 1 |
| Schindler, AE | 1 |
| Bell, JB | 1 |
| Kawano, M | 1 |
| Yasuda, H | 1 |
| Miyakawa, I | 1 |
| Mori, N | 1 |
| Dalla Pria, S | 1 |
| Moraes Lago, AH | 1 |
| Giorgino, F | 1 |
| Laureti, E | 1 |
| Haffen, K | 1 |
| Cèdard, L | 1 |
| Jaffe, RB | 2 |
| Pérez-Palacios, G | 2 |
| Lamont, KG | 2 |
| Givner, ML | 1 |
| Charreau, E | 1 |
| Villee, CA | 1 |
| Stárka, L | 1 |
| Janata, J | 1 |
| Pérez, AE | 1 |
| Pierce, GB | 1 |
| Pujol-Amat, P | 1 |
| Esteban-Altirriba, J | 1 |
| Venrell-Diaz, J | 1 |
| Tejero, A | 1 |
| Oriol-Bosch, A | 1 |
| Ribas-Mundo, J | 1 |
| Prats-Viñas, J | 1 |
| Weisberg, MG | 1 |
| Malkasian, GD | 1 |
| Pratt, JH | 1 |
| Gabos, P | 1 |
| Rosenfield, RL | 1 |
| Lawrence, AM | 1 |
| Liao, S | 1 |
| Landau, RL | 1 |
| Sachsse, W | 1 |
| Gilfrich, HJ | 1 |
| Overzier, C | 1 |
| Menzel, P | 2 |
| Jonas, A | 1 |
| Ances, IG | 1 |
| Connor, TB | 1 |
| Gallaher, EP | 1 |
| Migeon, CJ | 1 |
| Levin, HS | 1 |
| Ganis, FM | 1 |
| Rindt, W | 1 |
| Seidel, W | 1 |
| Gandar, R | 1 |
| Oertel, GW | 1 |
| Domínguez-Vargas, O | 1 |
| Loza-Arredondo, C | 1 |
| Rangel-Cabiedes, L | 1 |
| Zárate-Trevuño, A | 1 |
| Saez, JM | 2 |
| Morera, AM | 1 |
| De Peretti, E | 2 |
| Bertrand, J | 2 |
| Kelch, RP | 1 |
| Jenner, MR | 1 |
| Weinstein, R | 1 |
| Kaplan, SL | 1 |
| Grumbach, MM | 1 |
| Cardiff, C | 1 |
| Uden, V | 1 |
| Killinger, DW | 1 |
| Wilson, JD | 1 |
| Goldstein, JL | 1 |
| Lockwood, E | 1 |
| Ghosh, PC | 1 |
| Pennington, GW | 1 |
| Tipton, R | 1 |
| Frederich, A | 1 |
| Gower, DB | 1 |
| Bicknell, DC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pharmacokinetics of a Novel Oral Testosterone Undecanoate Formulation With Concomitant Inhibition of 5alpha-Reductase by Finasteride[NCT00842751] | Phase 2 | 11 participants (Actual) | Interventional | 2009-07-31 | Completed | ||
| Pharmacokinetics of Modified Slow-Release Oral Testosterone Over 10 Days in Normal Men With Experimental Hypogonadism[NCT01167829] | Phase 1 | 14 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Area under the curve of serum testosterone Pharmacokinetic measures time-weighted mean concentration calculated as area under the concentration curve (AUC) divided by time from initiation of dosing for the morning dose and corrected for differences in baseline hormone concentration. (NCT00842751)
Timeframe: 0,1,2,4,8,and 12-hour post dose
| Intervention | ng*hr/dL (Geometric Mean) |
|---|---|
| Acyline +Testosterone Undecanoate + Placebo | 471 |
| Acyline +Testosterone Undecanoate + 0.5mg Finasteride | 444 |
| Acyline +Testosterone Undecanoate + 1mg Finasteride | 543 |
Area under the curve of serum dihydrotestosterone (NCT00842751)
Timeframe: 0,1,2,4,8,and 12-hour post dose
| Intervention | ng*hr/dL (Geometric Mean) |
|---|---|
| Acyline +Testosterone Undecanoate + Placebo | 154 |
| Acyline + Testosterone Undecanoate + 0.5mg Finasteride | 118 |
| Acyline + Testosterone Undecanoate + 1mg Finasteride | 125 |
Area under the curve of serum estradiol (NCT00842751)
Timeframe: 0,1,2,4,8,and 12-hour post dose
| Intervention | ng*hr/dL (Geometric Mean) |
|---|---|
| Acyline +Testosterone Undecanoate + Placebo | 7.9 |
| Acyline + Testosterone Undecanoate + 0.5mg Finasteride | 6.5 |
| Acyline +Testosterone Undecanoate + 1mg Finasteride | 7.2 |
Free T normal range 4.7-18 ng/dL (NCT01167829)
Timeframe: baseline & day 9
| Intervention | ng/dL (Geometric Mean) | |
|---|---|---|
| Day 1-2 | Day 9-10 | |
| 300 mg Oral Testosterone | 24 | 21 |
Free T normal range 4.7-18 ng/dL (NCT01167829)
Timeframe: baseline & day 9
| Intervention | ng/dL (Geometric Mean) | |
|---|---|---|
| Day 1-2 | Day 9-10 | |
| 300 mg Oral Testosterone | 8.7 | 8.3 |
(NCT01167829)
Timeframe: baseline & day 9
| Intervention | ng/dL (Geometric Mean) | |
|---|---|---|
| Day 1 | Day 9 | |
| 300 mg Oral Testosterone | 233 | 142 |
(NCT01167829)
Timeframe: baseline & day 9
| Intervention | ng/dL (Geometric Mean) | |
|---|---|---|
| Day 1 | Day 9 | |
| 300 mg Oral Testosterone | 14 | 9 |
(NCT01167829)
Timeframe: baseline & day 9
| Intervention | ng/dL (Geometric Mean) | |
|---|---|---|
| Day 1 | Day 9 | |
| 300 mg Oral Testosterone | 31 | 22 |
initial pharmacokinetics [PK] (day 1) of oral testosterone dosed 3 times daily and the PK after 9 days of treatment (NCT01167829)
Timeframe: baseline & day 9
| Intervention | ng/dL (Geometric Mean) | |
|---|---|---|
| Day 1 | Day 9 | |
| Acyline and 300 mg Oral Testosterone | 924 | 741 |
(NCT01167829)
Timeframe: baseline & day 9
| Intervention | ng/dL (Geometric Mean) | |
|---|---|---|
| Day 1 | Day 9 | |
| Acyline and 300 mg Oral Testosterone | 96 | 69 |
(NCT01167829)
Timeframe: baseline & day 9
| Intervention | ng/dL (Geometric Mean) | |
|---|---|---|
| Day 1 | Day 9 | |
| 300 mg Oral Testosterone | 11 | 7 |
(NCT01167829)
Timeframe: baseline & day 9
| Intervention | ng/dL (Geometric Mean) | |
|---|---|---|
| Day 1 | Day 9 | |
| 300 mg Oral Testosterone | 27 | 19 |
initial 24-hour pharmacokinetics (PK) of oral testosterone dosed 3 times daily and post 24-hour PK after 9 days of treatment (NCT01167829)
Timeframe: baseline & day 9
| Intervention | ng/dL (Geometric Mean) | |
|---|---|---|
| Day 1 | Day 9 | |
| Acyine and 300 mg Oral Testosterone | 378 | 315 |
27 other studies available for dehydroepiandrosterone and Androgen Insensitivity Syndrome
| Article | Year |
|---|---|
STEROID SYNTHESIS IN THE CRYPTORCHID TESTES OF THREE CASES OF THE "TESTICULAR FEMINIZATION" SYNDROME.
Topics: Androgen-Insensitivity Syndrome; Androgens; Cryptorchidism; Dehydroepiandrosterone; Disorders of Sex | 1965 |
STEROID TRANSFORMATIONS IN VITRO BY TESTICULAR TISSUE FROM TWO CASES OF TESTICULAR FEMINISATION.
Topics: 17-alpha-Hydroxypregnenolone; Androgen-Insensitivity Syndrome; Androgens; Chromatography; Cryptorchi | 1965 |
Steroid metabolism in the gonads of a patient with testicular feminization. I. Metabolism of cholesterol, pregnenolone, progesterone and dehydroepiandrosterone in vitro.
Topics: Adolescent; Androgen-Insensitivity Syndrome; Cholesterol; Cryptorchidism; Dehydroepiandrosterone; Hu | 1975 |
Studies of in vitro steroid metabolism by testis tissue from 'complete' and 'incomplete' forms of testicular feminization.
Topics: 17-alpha-Hydroxypregnenolone; Adolescent; Adult; Androgen-Insensitivity Syndrome; Androstane-3,17-di | 1975 |
[Endocrinological and electron microscopical studies on the complete form of testicular feminization syndrome].
Topics: Adult; Androgen-Insensitivity Syndrome; Dehydroepiandrosterone; Estrone; Humans; Leydig Cells; Lutei | 1988 |
[Sexual ambiguity at birth: causes and proposal for a diagnostic scheme].
Topics: 17-alpha-Hydroxyprogesterone; Androgen-Insensitivity Syndrome; Androgens; Clitoris; Dehydroepiandros | 1985 |
[Study, in organ culture in vitro, of the metabolism of radioactive dehydroepiandrosterone and testosterone, by normal and intersex gonads from the chick embryo].
Topics: Androgen-Insensitivity Syndrome; Animals; Carbon Isotopes; Chick Embryo; Chromatography, Paper; Cult | 1968 |
De novo steriod sulfate biosynthesis.
Topics: 17-alpha-Hydroxypregnenolone; Acetates; Adrenal Glands; Androgen-Insensitivity Syndrome; Carbon Isot | 1968 |
Steroid metabolic pathways in feminizing testicular tissue.
Topics: 17-Ketosteroids; Acetone; Adolescent; Androgen-Insensitivity Syndrome; Androstanes; Biotransformatio | 1968 |
Steroid characteristics of the syndrome of testicular feminization.
Topics: Adult; Androgen-Insensitivity Syndrome; Chorionic Gonadotropin; Dehydroepiandrosterone; Disorders of | 1968 |
De novo formation and metabolism of steroid hormones in feminizing testes: biochemical and ultrastructural studies.
Topics: 17-Ketosteroids; Acetates; Adult; Androgen-Insensitivity Syndrome; Androstanes; Carbon Isotopes; Cho | 1969 |
Testicular feminizing syndrome and "pure" gonadal dysgenesis. Report of cases and in vitro studies with testes homogenate.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adolescent; Adult; Amenorrhea; Androgen-Insensitivity Sy | 1970 |
Testicular feminization syndrome. A review and report of 6 cases.
Topics: Adolescent; Adult; Aged; Amenorrhea; Androgen-Insensitivity Syndrome; Clitoris; Dehydroepiandrostero | 1970 |
Testicular feminization--hormonal evaluation. Report of a case.
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Adrenocortical Hyperfunction; Adult; Androgen-Insensitivit | 1970 |
Androgens and androgen responsiveness in the feminizing testis syndrome. Comparison of complete and "incomplete" forms.
Topics: Adolescent; Adult; Androgen-Insensitivity Syndrome; Androstanes; Chorionic Gonadotropin; Creatine; D | 1971 |
[Hard-to-classify forms of intersexuality. II. Familial male pseudohermaphroditism with lacking or supernumerary Y chromosome as mosaic].
Topics: 17-Ketosteroids; Adolescent; Androgen-Insensitivity Syndrome; Androsterone; Castration; Child; Dehyd | 1970 |
[Hard-to-classify forms of intersexuality. 3. Biosynthesis of steroids in testis of a case of male pseudohermaphroditism].
Topics: Androgen-Insensitivity Syndrome; Cholesterol; Dehydroepiandrosterone; Disorders of Sex Development; | 1970 |
Case of feminizing interstitial cell tumor of the testicle. Clinical and biochemical evaluation.
Topics: 17-Hydroxycorticosteroids; 17-Ketosteroids; Adult; Androgen-Insensitivity Syndrome; Androstanes; Chr | 1971 |
[Biosynthesis of steroids in a case of testicular feminization].
Topics: Adolescent; Androgen-Insensitivity Syndrome; Cholesterol; Dehydroepiandrosterone; Estrogens; Gonadot | 1971 |
[Patterns of steroid biosynthesis in feminizing and normal testicles].
Topics: Androgen-Insensitivity Syndrome; Androgens; Androsterone; Animals; Dehydroepiandrosterone; Humans; M | 1970 |
Further in vivo studies in male pseudohermaphroditism with gynecomastia due to a testicular 17-ketosteroid reductase defect (compared to a case of testicular feminization).
Topics: 17-Ketosteroids; Adolescent; Adult; Androgen-Insensitivity Syndrome; Androsterone; Dehydroepiandrost | 1972 |
Estradiol and testosterone secretion by human, simian, and canine testes, in males with hypogonadism and in male pseudohermaphrodites with the feminizing testes syndrome.
Topics: Adult; Androgen-Insensitivity Syndrome; Animals; Chorionic Gonadotropin; Chromatography, Thin Layer; | 1972 |
Estradiol and testosterone secretion by human, simian, and canine testes, in males with hypogonadism and in male pseudohermaphrodites with the feminizing testes syndrome.
Topics: Adult; Androgen-Insensitivity Syndrome; Animals; Chorionic Gonadotropin; Chromatography, Thin Layer; | 1972 |
Estradiol and testosterone secretion by human, simian, and canine testes, in males with hypogonadism and in male pseudohermaphrodites with the feminizing testes syndrome.
Topics: Adult; Androgen-Insensitivity Syndrome; Animals; Chorionic Gonadotropin; Chromatography, Thin Layer; | 1972 |
Estradiol and testosterone secretion by human, simian, and canine testes, in males with hypogonadism and in male pseudohermaphrodites with the feminizing testes syndrome.
Topics: Adult; Androgen-Insensitivity Syndrome; Animals; Chorionic Gonadotropin; Chromatography, Thin Layer; | 1972 |
Steroid biosynthesis in gonadal tissue from patients with testicular feminization.
Topics: Adult; Aging; Androgen-Insensitivity Syndrome; Carbon Isotopes; Chromatography; Dehydroepiandrostero | 1972 |
Evidence for increased cytoplasmic androgen binding in the submandibular gland of the mouse with testicular feminization.
Topics: Androgen-Insensitivity Syndrome; Androstenes; Animals; Castration; Centrifugation, Density Gradient; | 1972 |
Steroid excretion and metabolism by gonadal tissue from a subject with testicular feminization syndrome.
Topics: Adolescent; Androgen-Insensitivity Syndrome; Androsterone; Carbon Radioisotopes; Dehydroepiandroster | 1974 |
Children with male pseudohermaphroditism: endocrine and metabolic studies.
Topics: 17-Ketosteroids; Adolescent; Alcohol Oxidoreductases; Androgen-Insensitivity Syndrome; Androstenedio | 1971 |
Steroid excretion and biosynthesis, with special reference to 16-unsaturated C 19 steroids, in cases of testicular feminization and in a male pseudohermaphrodite.
Topics: Adolescent; Adrenocorticotropic Hormone; Adult; Androgen-Insensitivity Syndrome; Androgens; Androste | 1972 |